Mark Purcell
Stock Analyst at Morgan Stanley
(0.85)
# 3,978
Out of 5,161 analysts
6
Total ratings
33.33%
Success rate
-8.78%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Purcell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNY Sanofi | Upgrades: Overweight | $56 → $58 | $43.63 | +32.94% | 2 | Sep 8, 2025 | |
| NVS Novartis AG | Initiates: Equal-Weight | $114 | $154.25 | -26.09% | 1 | Jan 23, 2024 | |
| GSK GSK plc | Initiates: Equal-Weight | $44 | $54.28 | -18.94% | 1 | Jan 23, 2024 | |
| AZN AstraZeneca | Initiates: Overweight | $85 | $192.50 | -55.84% | 1 | Jan 23, 2024 | |
| NVO Novo Nordisk | Initiates: Overweight | $120 | $38.02 | +215.62% | 1 | Jan 23, 2024 |
Sanofi
Sep 8, 2025
Upgrades: Overweight
Price Target: $56 → $58
Current: $43.63
Upside: +32.94%
Novartis AG
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $114
Current: $154.25
Upside: -26.09%
GSK plc
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $44
Current: $54.28
Upside: -18.94%
AstraZeneca
Jan 23, 2024
Initiates: Overweight
Price Target: $85
Current: $192.50
Upside: -55.84%
Novo Nordisk
Jan 23, 2024
Initiates: Overweight
Price Target: $120
Current: $38.02
Upside: +215.62%